November 17th, 2026Gilead Signs Royalty-Free Licensing Deals to Broaden Access to Obeldesivir Gilead signs royalty-free licensing agreements with three generic manufacturers to expand future access to its investigational antiviral obeldesivir. Read more
November 17th, 2026FDA Approves Cosentyx for Polymyalgia Rheumatica, Wilserdly for ER-Positive ESR1-Mutated Advanced Breast Cancer FDA submitted approvals for Novartis’s Cosentyx and Roche’s Wilserdly. Read more
November 16th, 2026The Hidden Risk in Pharma’s AI RushSustainable competitive advantage requires combining proprietary evidence, AI, and human expertise—not substituting one for another.Read more
November 11th, 2026FDA Approves Pimjetmi for Patients With Tenosynovial Giant Cell TumorFDA has approved Merck KGaA’s Pimjetmi, an oral CSF-1R inhibitor, for adults with symptomatic tenosynovial giant cell tumors. Read more
November 10th, 2026FDA Requests Updated Safety Label Warning Across All GLP-1 Receptor Agonist for Potential Risk of NAION FDA is requiring manufacturers of all GLP-1 receptor agonists to add a warning for a potential increased risk of NAION. Read more
November 10th, 2026FDA Approves asundexian for Secondary Stroke Risk Reduction FDA approves Bayer’s asundexian (Sunharbo), the first Factor XIa inhibitor, for secondary stroke prevention. Read more
November 9th, 2026Single Partner Platforms: Enhancing the Prescription Journey for ManufacturersSingle-partner platforms can unify manufacturers, prescribers, and patients to eliminate gaps, cut costs, and boost treatment adherence.Read more
November 9th, 2026argenx Acquires Unnatural Products Inc. to Expand Immunology Capabilities argenx acquires Unnatural Products, adding a macrocyclic peptide discovery platform to complement its antibody engineering. Read more